Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2006

VPg of murine norovirus binds translation initiation factors in
infected cells
Katie F. Daughenbaugh
Montana State University - Bozeman

Christiane E. Wobus
Washington University School of Medicine in St. Louis

Michele E. Hardy
Montana State University - Bozeman

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Part of the Medicine and Health Sciences Commons

Recommended Citation
Daughenbaugh, Katie F.; Wobus, Christiane E.; and Hardy, Michele E., ,"VPg of murine norovirus binds
translation initiation factors in infected cells." Virology Journal. 3,. 33. (2006).
https://digitalcommons.wustl.edu/open_access_pubs/173

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Virology Journal

BioMed Central

Open Access

Research

VPg of murine norovirus binds translation initiation factors in
infected cells
Katie F Daughenbaugh1, Christiane E Wobus2 and Michele E Hardy*1
Address: 1Veterinary Molecular Biology, Montana State University, Bozeman, MT, USA and 2Department of Pathology and Immunology,
Washington University School of Medicine, St Louis, MO, USA
Email: Katie F Daughenbaugh - katief@montana.edu; Christiane E Wobus - cwobus@wustl.edu; Michele E Hardy* - mhardy@montana.edu
* Corresponding author

Published: 23 May 2006
Virology Journal 2006, 3:33

doi:10.1186/1743-422X-3-33

Received: 06 March 2006
Accepted: 23 May 2006

This article is available from: http://www.virologyj.com/content/3/1/33
© 2006 Daughenbaugh et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract
Background: Norovirus genomic and subgenomic RNAs are covalently linked at the 5' nucleotide
to a 15 kD protein called VPg. VPg of two human norovirus strains binds translation initiation factor
eIF3 and other eIFs in vitro, suggesting VPg functions in initiation of protein synthesis on viral RNA.
Human norovirus strains are not cultivable, and thus experimental evidence of interactions
between VPg and eIFs in infected cells has been lacking. We used the cultivable murine norovirus
MNV-1 as a model to study interactions between VPg and eIFs in infected cells.
Results: As shown previously for human norovirus VPg, MNV-1 VPg bound eIF3, eIF4GI, eIF4E,
and S6 ribosomal protein in cell extracts by GST pull-down assay. Importantly, MNV-1 VPg coprecipitated eIF4GI and eIF4E from infected macrophages, providing evidence that VPg interacts
with components of the translation machinery in norovirus infected cells.
Conclusion: The interactions between MNV-1 VPg and eIFs completely mimic those reported for
the human norovirus VPg, illustrating the utility of MNV-1 as a relevant molecular model to study
mechanisms of human norovirus replication.

Background
Noroviruses constitute a genus in the family Caliciviridae
and are the most frequent cause of foodborne viral gastroenteritis epidemics [1]. The norovirus genome is a 7.7 kb,
positive-sense, single-stranded RNA that is polyadenylated at the 3' end. The genome codes for three open
reading frames. ORF1 encodes the nonstructural proteins
that are synthesized as a polyprotein precursor and processed by the 3C-like viral protease. ORF2 and ORF3
encode the capsid protein VP1 and minor structural protein VP2, respectively. Both VP1 and VP2 are synthesized
from a subgenomic RNA that is 3' coterminal with the
genomic RNA. Instead of a 7-methylguanosine (m7G) cap
structure at the 5' end, genomic and subgenomic RNAs are

covalently linked to a viral protein called VPg, for viral
protein genome-linked. The linkage between VPg and the
5' nucleotide has been demonstrated experimentally only
for the animal caliciviruses [2,3], but by analogy, it is
assumed that VPg also is linked to norovirus genomes.
The function(s) of VPg in the norovirus replication cycle
are not known, but data that this small protein functions
in translation initiation are accumulating. Studies of animal caliciviruses showed VPg is necessary for infectivity of
native viral RNA [2], but an m7G cap can confer infectivity
to in vitro synthesized feline calicivirus (FCV) genomic
RNA transcripts [4]. Together, data from these studies conclude that the m7G cap functionally substitutes for VPg
when transfecting calicivirus RNA into cells. We previPage 1 of 7
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Figure VPg
MNV-1
1 and NV VPg share significant amino acid sequence identity
MNV-1 VPg and NV VPg share significant amino acid sequence identity. Sequences encoding MNV-1 VPg and NV
VPg were aligned with ClustalW. Asterisks indicate identical residues. Semicolons are conservative substitutions. Amino acid
numbers correspond to the position in the ORF1 polyprotein.

ously reported that VPg of the Norwalk (NV) and Snow
Mountain (SMV) strains of human norovirus bound
translation initiation factor eIF3, providing the first direct
evidence that VPg may function in ribosome recruitment
to viral RNA [5]. Recently, an interaction between FCV
VPg and translation initiation factor eIF4E was reported,
and this interaction was required for translation of FCV
VPg-linked RNA in vitro [6].
Most cellular mRNAs are translated by a cap-dependent
mechanism driven by protein-protein and protein-RNA
interactions between translation initiation factors (eIFs)
and mRNA [7]. Cap-dependent translation initiates with
binding of the eIF4F complex that consists of eIF4E,
eIF4GI and eIF4A, to the m7G cap structure. Recruitment
of the 43S pre-initiation complex composed of eIF3, 40S
ribosomal subunits, and initiator tRNA to mRNA occurs
primarily through interactions between eIF4GI and eIF3
[8,9]. This 48S complex scans the mRNA to initiate translation at the first strong context AUG. Cap-independent
translation is mediated by extensively structured regions
of RNA called internal ribosome entry sites (IRES). These
elements are found in genomes of picornaviruses, pestiviruses, and insect viruses of the Dicistroviridae family [10],
and some cellular mRNAs as well (reviewed in [11]. Initiation complexes assemble internal to the 5' end of the
RNA molecule and translation initiates at, or shortly
downstream, of the IRES. The fact that norovirus RNAs
lack a m7G cap, are 5' nucleotide-protein linked, and have
5' untranslated regions (UTR) of only 10 nucleotides suggest translation initiation on norovirus RNA mediated by
VPg proceeds in a manner distinct from cap-dependent
and IRES-dependent mechanisms.
VPg of human noroviruses binds directly to eIF3, is
present in complexes with other eIFs, and inhibits transla-

tion of mRNAs that have different eIF requirements for
functional initiation complex assembly [5]. All of these
data were obtained using purified protein and cell-free
assays. Human noroviruses do not grow in cell culture,
and therefore, connecting this eIF binding data with
events that occur in norovirus infected cells is challenging.
A significant advance in the field was the discovery of a
murine norovirus (MNV-1) that replicates in cultured
macrophages and dendritic cells [12,13]. MNV-1 is the
only norovirus that grows in culture, and is closely related
genetically to the human norovirus strains [12]. Therefore, we used MNV-1 to address questions about the functional significance of interactions between VPg and eIFs
observed with the human noroviruses. In addition, determining whether protein-protein interactions are the same
between the human and murine viruses would establish
whether MNV-1 constitutes a relevant molecular model
for the non-cultivable human strains. Our data show that
MNV-1 VPg binds eIFs in infected cells, and that interactions between MNV-1 VPg and eIFs are the same as those
that occur between eIFs and human norovirus VPg. These
findings indicate that MNV-1 represents an important
molecular tool for the study of human noroviruses in tissue culture.

Results
Recombinant MNV-1 VPg binds eIF3, eIF4GI, eIF4E, and S6
ribosomal protein in vitro
VPg of genogroup I NV and genogroup II SMV share 68%
amino acid sequence identity and both bind purified eIF3
and to eIF3 in cell extracts [5]. VPg sequences of MNV-1
and NV were aligned and share 54% identity (Figure 1).
The N- and C-terminal domains showed the highest level
of conservation, and flank a central variable region that
includes a glycine-rich, nine amino acid insertion in NV
VPg. Interpreted in the context of the inferred function of

Page 2 of 7
(page number not for citation purposes)

Virology Journal 2006, 3:33

A

http://www.virologyj.com/content/3/1/33

B
ST
G

Pg
-V
ST
G
-1
NV
M

C
ST
G

-V
Pg
MN
V1G
ST

GS
T

111 kD
92 kD

D
ST
G

Pg
-V
ST
G
-1
NV
M

E
ST
G

Pg
-V
ST
G
-1
NV
M

eIF4GI

*

eIF3a
eIF3b
eIF3c

Pg
-V
ST
G
-1
NV
M

111 kD
92 kD

111 kD

111 kD

92 kD

92 kD

eIF3d
53 kD

53 kD

53 kD

53 kD

53 kD

36 kD

36 kD

29 kD

29 kD

36 kD

S6

36 kD
36 kD
29 kD

eIF4E

29 kD

29 kD

anti-eIF3

anti-phospho-eIF4GI

anti-eIF4E

anti-S6

Figure GST-VPg
MNV-1
2
binds eIF3, phospho-eIF4GI, eIF4E, and S6 ribosomal protein by pull-down assay
MNV-1 GST-VPg binds eIF3, phospho-eIF4GI, eIF4E, and S6 ribosomal protein by pull-down assay. GST and
MNV-1 GST-VPg were expressed in bacteria and purified as described in the text. A) Purified GST and GST-VPg, analyzed by
10% SDS-PAGE and stained with Coomassie blue. Proteins in the pull-down eluates were subjected to SDS-PAGE, and then
immunoblot probed with (B) anti-eIF3, (C) anti-phospho-eIF4GI, (D) anti-eIF4E, and (E) anti-S6 ribosomal protein. Blots were
developed with ECL chemiluminescent substrate. The asterisk in B indicates a protein identified as eIF4GI.

VPg in translation, an overall amino acid sequence identity of 54%, and conservation in both N and C-terminal
domains, suggested that MNV-1 could have similar eIF
binding properties as NV VPg.
To test if MNV-1 VPg binds eIFs in a cell-free system, VPg
was expressed as a GST fusion protein in bacteria, purified
(Figure 2A), and used in pull-down assays with extracts
prepared from RAW 264.7 macrophages as previously
described [5]. Proteins in pull-down eluates were analyzed by immunoblots probed with antibodies to eIF3
(Figure 2B), phospho-eIF4GI (Figure 2C), eIF4E (Figure
2D), and S6 ribosomal protein (Figure 2E). Similar to data
obtained for NV VPg, all of these factors bound MNV-1
GST-VPg.
eIF3 is a large complex composed of 12 subunits [7]. Four
of these subunits, eIF3a, eIF3b/eIF3c doublet [14], and
eIF3d, were identified in the VPg pull-down eluates. Identification was made by the banding pattern that is
observed for eIF3 when this polyclonal antibody is used as
a probe [14]. The reasons for detecting only a few of the
subunits in the eluates are not known, but this large complex may be unstable under conditions of the assay. The
anti-eIF3 serum contains antibodies to eIF4GI [14]. Therefore, the high molecular weight protein detected in the
immunoblots probed with this serum likely represents
eIF4GI. The presence of this factor in the pull-down reactions was confirmed by probing the blots with an antiphospho-eIF4GI antibody (Figure 2C). The lower molec-

ular weight products that reacted with the phosphoeIF4GI antibody are interpreted to be degradation products of the full-length protein. Taken together, the data
from the pull-down assays and previous results show that
the interactions between NV VPg and eIFs and between
MNV-1 VPg and eIFs are the same.
VPg and eIFs co-precipitate from MNV-1 infected RAW
264.7 cells
To investigate interactions between VPg and eIFs in
infected cells, RAW 264.7 cells were infected with MNV-1
and immunoprecipitations (IP) were performed following established protocols [13,15]. MNV-1 VPg was present
in infected but not mock infected cell lysate (Figure 3A,
lane 2, middle panel) and antibodies to VPg immunoprecipitated VPg (Figure 3A, lane 4, middle panel) and phospho-eIF4GI (Figure 3A, lane 4, top panel). The polar
nature of VPg results in a somewhat diffuse migration in
SDS polyacrylamide gels instead of a sharp band (Daughenbaugh and Hardy, unpublished observations). In the
reciprocal experiment, anti-phospho-eIF4GI antibody
precipitated phospho-eIF4GI (Figure 3A, lanes 5 and 6,
top panel) and MNV-1 VPg (Figure 3A, lane 6, middle
panel). This demonstrates MNV-1 VPg binds eIF4GI in
virus-infected cells.

Three additional observations about eIF4GI can be made
from these experiments. First, there was a reproducible
increase in the amount of phospho-eIF4GI in infected
cells compared to mock infected cells (Figure 3A lanes 1,
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Figure
Phospho-eIF4GI
3
and eIF4E co-immunoprecipitate with VPg from MNV-1 infected RAW 264.7 cells
Phospho-eIF4GI and eIF4E co-immunoprecipitate with VPg from MNV-1 infected RAW 264.7 cells. A) Mock
infected or infected cell lysates were subjected to immunoprecipitation with anti-MNV-1 VPg (lanes 3 and 4) or anti-phosphoeIF4GI (lanes 5 and 6). Immunoblots were probed with the relevant antibody indicated to the left of the panels. Lanes 1 and 2
are control lysates that did not receive antibody. B) Mock infected or infected cell lysates probed with anti-eIF4GI.
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2, 5 and 6, top panels). However, the levels of total
eIF4GI, irrespective of its phosphorylation status, were
similar in mock and infected cell lysates (Figure 3B) suggesting that differences in the amount of phospho-eIF4GI
cannot be attributed to increased expression of eIF4GI. It
has been reported that the amount of eIF4GI phosphorylated at serines 1108, 1148 and 1192 increases in
response to serum stimulation, and phosphorylation at
these sites is modulated by the N terminal third of the protein [16]. Potential mechanisms were proposed, including
de-repression of eIF4GI by direct phosphorylation of the
N terminus, or alternatively, interactions with an eIF4GI
binding partner to expose the C terminal domain to
kinase activity [16]. It is conceivable that MNV-1 infection
could result in activation of kinases that modulate the
activity of eIF4GI. An alternative and not mutually exclusive possibility is that direct interactions between eIF4GI
and VPg alter the conformation of eIF4GI to a form where
the C terminal serine residues are phosphorylated.
A second observation is that several eIF4GI degradation
products were found in cell lysate (Figure 3A, lanes 1 and
2, top panel), or when protein was immunoprecipitated
with anti-phospho-eIF4GI antibody (Figure 3A, lanes 5
and 6, top panel). In contrast, anti-VPg antibody exclusively precipitated full-length eIF4GI. If the interaction
between VPg and eIF4GI is direct, these data suggest a
binding site for VPg could reside in the N-terminal twothirds of eIF4GI, since the phospho-eIF4GI antibody recognizes the C terminal third of the protein. If the interaction between VPg and eIF4GI is indirect, full length
eIF4GI could have been brought down by a potential
direct interaction between VPg and eIF4E because an
eIF4E binding site resides in the N terminus of eIF4GI
[17].
Finally, the presence of identical degradation products in
both mock and infected cell lysates suggests that, in contrast to FCV infections [18], eIF4GI is not detectably
cleaved during MNV-1 infection. Although we have not
performed extensive analysis of eIF4GI cleavage, these
data are consistent with reports that recombinant norovirus 3C protease (MD-145 strain) does not cleave eIF4GI in
vitro [19]. This degradation pattern was not observed
when mock and infected cell lysates were probed with
antibody to total eIF4GI (Figure 3B). The reason for this
discrepancy is not entirely clear, but we have observed
some variability in the stability of eIF4GI in RAW 264.7
cells lysates. The degradation products also could be C-terminal fragments of the protein not recognized by the
eIF4GI antibody made to an N-terminal peptide that was
used to detect the full-length protein.
Goodfellow and co-workers recently reported that FCV
VPg co-precipitates eIF4E from infected cells, and that this

http://www.virologyj.com/content/3/1/33

interaction is necessary for translation of FCV VPg-linked
RNA in vitro [6]. To determine if MNV-1 VPg was associated with eIF4E in infected cells, we immunoprecipitated
VPg from infected cell lysates and probed samples by
immunoblot for eIF4E. eIF4E was found in similar quantities in mock and infected cell lysates in the absence of
antibody (Figure 3A, lanes 1 and 2, bottom panel), and
co-precipitated with VPg from infected cells (Figure 3A,
lanes 3 and 4, bottom panel). These data indicate that
MNV-1 VPg and eIF4E interact in infected cells. Further
studies are necessary to determine if this interaction with
MNV-1 VPg is direct, or if eIF4E is detected as a result of
interactions with other components of eIF4F.

Discussion
We and others put forth the idea that VPg functions in
translation initiation on VPg-linked RNA through interactions with eIFs [3,5,6,20]. The data presented here provide
experimental evidence of interactions between VPg and
eIFs in norovirus infected cells, and strengthen the assertion that the interactions previously defined for NV VPg
by cell-free assays are relevant and functional.
eIF3, eIF4GI, and eIF4E were detected in GST pull-down
eluates of both NV VPg [5] and MNV-1 VPg (this study),
and eIF4GI and eIF4E were found in co-immunoprecipitates with VPg from MNV-1 infected cells. While these
assays do not prove a direct interaction between VPg and
these translation initiation factors, they strongly suggest
VPg interacts with one or more components of the eIF4F
complex. These observations lend support to previous
suggestions that VPg is a protein cap analogue with respect
to binding interactions with eIF4F. We further suggest that
the role of VPg in ribosome recruitment is more complex
than providing a target for eIF4F binding. VPg is a 15 kD
protein covalently linked to the 5' end of an RNA that has
a 10 nucleotide 5' UTR. If VPg functions simply as a protein cap, then by analogy to capped mRNA, translation
initiation at nucleotide 11 would be inefficient [21].
Moreover, direct interactions between VPg and eIF3 [5]
point to the potential involvement of VPg in 43S pre-initiation complex recruitment. Sequence conservation
between VPg and initiation factor eIF1A, a factor important in AUG codon recognition and ternary complex
recruitment [22], has been noted for NV VPg [23], and a
similar degree of conservation exists between MNV-1 VPg
and eIF1A (data not shown). We have suggested a model
of translation initiation on NV VPg-linked RNA that we
now extend to MNV-1, whereby a direct interaction
between VPg and eIF3, and likely components of eIF4F,
positions the ribosome at the initiator AUG without
ribosome scanning. This model implies numerous concerted interactions between norovirus VPg and eIFs,
including the 40S ribosome, additional to the interactions
reported so far.
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Studies with animal calicivirus strains in the Vesivirus
genus of the family, particularly FCV, have contributed a
large body of data on mechanisms of calicivirus replication [19,24-26]. These data provide a good foundation on
which to build models of norovirus replication by analogy. However, these analogies have limitations, largely
due to the genetic divergence between animal caliciviruses
and noroviruses. For example, FCV VPg and NV VPg share
only 18% amino acid identity, and thus far we and others
[6] have been unable to detect interactions between FCV
VPg and eIF3 or eIF4GI in GST pull-down assays. We have
not performed extensive binding studies with FCV VPg to
determine what interactions may occur that are different
from those observed with the norovirus VPg, but it is
probable that specific interactions and mechanistic details
differ between the animal caliciviruses and noroviruses.
These observations exemplify the importance of MNV-1
as a molecular model for human noroviruses, as interactions between MNV-1 VPg and eIFs precisely mimic those
reported for NV VPg.
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phate, 5 mM NaF, 2.5% glycerol, and one mini protease
inhibitor cocktail tablet (Roche Biochemicals). Lysates
were clarified by centrifugation for 5 minutes at 10,000 ×
g at 4°C. Ten µl (2%) of each sample was retained as controls and not subjected to immunoprecipitation. The
remaining lysate was incubated with the indicated antibody and rotated gently for two hours at 4°C. Anti-phospho-eIF4GI (Cell Signaling Technologies) was used at a
dilution of 1:100 and anti-MNV-1 VPg (provided by Kim
Green, NIAID) was used at a dilution of 1:1000. Thirty µl
of Gamma Bind Plus Sepharose beads (GE Amersham
Biosciences) prepared in IP buffer were added, and complexes were rotated for one hour at 4°C. Beads were collected by centrifugation for 2 minutes at 500 × g at 4°C,
and then washed four times with wash buffer containing
20 mM Tris-HCl pH 7.5, 50 mM NaCl, and 0.1% NP-40.
Complexes were eluted from the beads by incubation on
ice for 10 minutes in 25 µl elution buffer (0.75% wt/vol
glycine in water, pH 2.2). The beads were collected for 2
minutes at 500 × g at 4°C. Supernatants were transferred
to fresh tubes containing 0.9 µl 2 M Tris base.

Methods
RAW 264.7 Cells
RAW 264.7 cells (ATCC TIB-71) were maintained in
DMEM containing 10% FBS (Atlanta Biologicals), 10 mM
Hepes, 4 mM L-glutamine, 4.5 g/L glucose, and 1.5 g/L
sodium bicarbonate.
Construction of GST-MNV-1 VPg and GST pull-down
assays
MNV-1 VPg was amplified from pSPORT-T7-MNV-1 (gift
from H. Virgin, Washington University School of Medicine) using the primers MNV-VPg/BamHI(+) 5'-cgcggatccggaaagaagggcaagaac-3' and MNV-VPg/XhoI(-) 5'ccgctcgagctcaaagttgatcttctcg-3'. Restriction sites for cloning are underlined. Reactions were assembled using the
KOD kit (Novagen) according to instructions provided by
the manufacturer. Amplification conditions consisted of
25 cycles of 98°C for 15 seconds, 58°C for 3 seconds, and
72°C for 5 seconds. The amplification product was cloned
into pGEX-4-T1 (GE Amersham Biosciences) using
BamHI and XhoI restriction enzymes. Expression and
purification of GST-MNV-VPg, as well as pull-down assays
using RAW 264.7 cell lysates, were performed as described
previously [5].
Immunoprecipitations
RAW 264.7 cells were grown to 90% confluence in 10 cm
dishes, and infected with MNV-1 for 17 hours at a multiplicity of infection of 1.5 pfu/cell. Cells were harvested in
1 mL of cold medium and pelleted for 5 minutes at 3000
× g at 4°C. Pellets were washed twice in cold phosphatebuffered saline, and lysed by incubation on ice for 30
minutes in 500 µL IP buffer containing 20 mM Tris-HCl
pH 7.5, 50 mM NaCl, 0.1% NP-40, 10 mM β-glycerophos-

Western immunoblots
Immunoprecipitation and pull-down samples were subjected to SDS-PAGE and transferred to nitrocellulose,
blocked in 10% nonfat dry milk and incubated with the
indicated antibody overnight at room temperature. Antibodies used were anti-phospho-eIF4GI at 1:1000, anti-S6
ribosomal protein and anti-eIF4E (both from Cell Signaling Technologies) at 1:1000, anti-eIF3 (kindly provided
by John Hershey, UC Davis) at 1:2000, anti-eIF4GI (N-20,
Santa Cruz Biotechnology) at 1:1000, and anti-MNV-1
VPg at 1:2000. Appropriate horseradish peroxidase-conjugated secondary antibodies were used at dilutions of
1:3000. Blots were developed with ECL chemiluminescent substrate (GE Amersham Biosciences) and exposed
to film for similar lengths of time.
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